Sunshine Biopharma Statistics
Share Statistics
Sunshine Biopharma has 4.56M
shares outstanding. The number of shares has increased by -85.7%
in one year.
| Shares Outstanding | 4.56M |
| Shares Change (YoY) | -85.7% |
| Shares Change (QoQ) | 35.44% |
| Owned by Institutions (%) | 0% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 10,988 |
| FTD / Avg. Volume | 0.76% |
Short Selling Information
The latest short interest is 259K, so 5.68% of the outstanding
shares have been sold short.
| Short Interest | 259K |
| Short % of Shares Out | 5.68% |
| Short % of Float | 5.69% |
| Short Ratio (days to cover) | 1.97 |
Valuation Ratios
The PE ratio is -0.41 and the forward
PE ratio is null.
Sunshine Biopharma's PEG ratio is
0.
| PE Ratio | -0.41 |
| Forward PE | n/a |
| PS Ratio | 0.06 |
| Forward PS | 0.1 |
| PB Ratio | 0.09 |
| P/FCF Ratio | -0.14 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Sunshine Biopharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.11,
with a Debt / Equity ratio of 0.04.
| Current Ratio | 4.11 |
| Quick Ratio | 2.33 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | -0.18 |
| Debt / FCF | -0.06 |
| Interest Coverage | -662.43 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $670,659.29 |
| Profits Per Employee | $-98,733 |
| Employee Count | 52 |
| Asset Turnover | 1.14 |
| Inventory Turnover | 2.15 |
Taxes
| Income Tax | -234.86K |
| Effective Tax Rate | 4.37% |
Stock Price Statistics
The stock price has increased by -85.33% in the
last 52 weeks. The beta is 1.18, so Sunshine Biopharma's
price volatility has been higher than the market average.
| Beta | 1.18 |
| 52-Week Price Change | -85.33% |
| 50-Day Moving Average | 1.51 |
| 200-Day Moving Average | 2.46 |
| Relative Strength Index (RSI) | 57.83 |
| Average Volume (20 Days) | 1,436,350 |
Income Statement
In the last 12 months, Sunshine Biopharma had revenue of 34.87M
and earned -5.13M
in profits. Earnings per share was -7.32.
| Revenue | 34.87M |
| Gross Profit | 10.67M |
| Operating Income | -5.81M |
| Net Income | -5.13M |
| EBITDA | -5.15M |
| EBIT | -5.38M |
| Earnings Per Share (EPS) | -7.32 |
Full Income StatementBalance Sheet
The company has 9.69M in cash and 952.48K in
debt, giving a net cash position of 8.73M.
| Cash & Cash Equivalents | 9.69M |
| Total Debt | 952.48K |
| Net Cash | 8.73M |
| Retained Earnings | -69.04M |
| Total Assets | 30.56M |
| Working Capital | 19.65M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -12.53M
and capital expenditures -2.32M, giving a free cash flow of -14.85M.
| Operating Cash Flow | -12.53M |
| Capital Expenditures | -2.32M |
| Free Cash Flow | -14.85M |
| FCF Per Share | -21.16 |
Full Cash Flow StatementMargins
Gross margin is 30.6%, with operating and profit margins of -16.67% and -14.72%.
| Gross Margin | 30.6% |
| Operating Margin | -16.67% |
| Pretax Margin | -15.4% |
| Profit Margin | -14.72% |
| EBITDA Margin | -14.78% |
| EBIT Margin | -16.67% |
| FCF Margin | -42.59% |
